HK1152947A1 - Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6 - Google Patents

Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6

Info

Publication number
HK1152947A1
HK1152947A1 HK11106921.8A HK11106921A HK1152947A1 HK 1152947 A1 HK1152947 A1 HK 1152947A1 HK 11106921 A HK11106921 A HK 11106921A HK 1152947 A1 HK1152947 A1 HK 1152947A1
Authority
HK
Hong Kong
Prior art keywords
trpv6
inhibiting
cancer treatment
calcium channel
channel activity
Prior art date
Application number
HK11106921.8A
Other languages
English (en)
Chinese (zh)
Inventor
John M Stewart
Original Assignee
Soricimed Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soricimed Biopharma Inc filed Critical Soricimed Biopharma Inc
Publication of HK1152947A1 publication Critical patent/HK1152947A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11106921.8A 2008-03-19 2011-07-05 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6 HK1152947A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790308P 2008-03-19 2008-03-19
PCT/CA2009/000343 WO2009114943A1 (en) 2008-03-19 2009-03-18 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity

Publications (1)

Publication Number Publication Date
HK1152947A1 true HK1152947A1 (en) 2012-03-16

Family

ID=41090452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106921.8A HK1152947A1 (en) 2008-03-19 2011-07-05 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6

Country Status (7)

Country Link
US (4) US8211857B2 (xx)
EP (1) EP2268665B1 (xx)
JP (1) JP5749154B2 (xx)
CA (1) CA2718949C (xx)
ES (1) ES2530091T3 (xx)
HK (1) HK1152947A1 (xx)
WO (1) WO2009114943A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114943A1 (en) 2008-03-19 2009-09-24 Bioprospecting Nb, Inc. Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity
CA2766272C (en) * 2009-06-26 2021-02-09 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CA2924224C (en) * 2012-09-14 2023-03-21 John M. Stewart Trpv3 agonists for the treatment of skin conditions
CA3003932A1 (en) * 2015-11-02 2017-05-11 University Of New Brunswick Soricid based peptides for the treatment of resorptive bone disease
WO2019108920A1 (en) * 2017-12-01 2019-06-06 Soricimed Biopharma Inc. Trpv6 inhibitors and combination therapies for treating cancers
CN113072634B (zh) * 2021-03-17 2022-07-12 西安交通大学 一种胞膜瞬时受体电位c6通道免疫原性短肽及其疫苗和抗心室纤维化的制药应用
AU2022365387A1 (en) 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JPH10236963A (ja) 1997-02-26 1998-09-08 Sagami Chem Res Center カルシウムチャンネル拮抗剤
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
US6946475B1 (en) * 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
JP4932994B2 (ja) * 1999-04-07 2012-05-16 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 抗癌性カルシウムチャンネル遮断薬
US6534642B1 (en) * 1999-07-09 2003-03-18 Matthias A. Hediger Compositions corresponding to a calcium transporter and methods of making and using same
AU2001287639A1 (en) * 2000-07-28 2002-02-13 Ulrich Wissenbach Trp8, trp9 and trp10, markers for cancer
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
CA2544467C (en) * 2002-11-18 2014-02-18 John M. Stewart Paralytic peptide for use in neuromuscular therapy
WO2009114943A1 (en) 2008-03-19 2009-09-24 Bioprospecting Nb, Inc. Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity

Also Published As

Publication number Publication date
WO2009114943A1 (en) 2009-09-24
JP5749154B2 (ja) 2015-07-15
EP2268665A4 (en) 2011-05-18
CA2718949C (en) 2021-05-04
US20140187493A1 (en) 2014-07-03
EP2268665B1 (en) 2014-11-12
US10058587B2 (en) 2018-08-28
EP2268665A1 (en) 2011-01-05
US8618058B2 (en) 2013-12-31
ES2530091T3 (es) 2015-02-26
CA2718949A1 (en) 2009-09-24
US20110071089A1 (en) 2011-03-24
US20160206694A1 (en) 2016-07-21
US9303077B2 (en) 2016-04-05
US20120316119A1 (en) 2012-12-13
US8211857B2 (en) 2012-07-03
JP2011517442A (ja) 2011-06-09

Similar Documents

Publication Publication Date Title
IL229878A (en) Cancer Treatment Compounds
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
IL199907A0 (en) Composition for treatment of pancreatic cancer
EP1996612A4 (en) COMPOSITIONS FOR THE TREATMENT OF CANCER
FI3517534T3 (fi) Yhdisteet jotka ovat hyödyllisiä syövän hoidossa
EP2152722A4 (en) COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER
SI2310034T1 (sl) Peptidi za zdravljenje beta-amiloidoz
HK1152947A1 (en) Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6
IL209156A0 (en) Opioid composition for treating skin lesions
EP1987838A4 (en) NEW CONNECTION TO TUMOR THERAPY
IL213398A0 (en) Compounds for treating cancer
EP2327402A4 (en) COMPOSITION WITH 4-O-METHYLHONOKIOL FOR THE TREATMENT OR PREVENTION OF AMYLOID-RELATED DISEASES
IL211904A0 (en) Composition for treating disese
EP2374463A4 (en) COMPOSITION FOR IMPROVING RADIATION THERAPY FOR CANCER
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
EP1986656A4 (en) WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
EP2255825A4 (en) COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES
EP2473506A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0707556D0 (en) Treatment for cancer
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
EP2329824A4 (en) NEW PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NOZIZEPTIVE PAIN